Zydus Lifesciences Limited announced a 30% year-on-year increase in net profit, totaling ₹1,023.5 crore for the quarter ending December 31, 2024, primarily fueled by strong performance in its US formulations business. The pharmaceutical company’s revenue from operations also saw a rise of 17% to reach ₹5,269.1 crore compared to the previous year.
Trading at ₹977.45 on the NSE at 2.30 pm, Zydus Lifesciences Limited’s shares were up by ₹3.45 or 0.35%.
The company’s US formulations business, which represents 47% of consolidated revenues, experienced a significant growth of 31% to reach ₹2,409.6 crore. During the quarter, Zydus introduced five new products in the US market, including three brands of Sitagliptin.
Conversely, the India business contributed 38% of the total revenues, registering a 7% growth to ₹1,947 crore. The consumer wellness segment of the company also saw a 13% year-on-year growth with a 4.8% volume increase.
Furthermore, the EBITDA for the quarter surged by 26% to ₹1,387.6 crore, with margins improving by 180 basis points to 26.3%. As of December 31, 2024, the company maintained a strong financial position with a net cash reserve of ₹3,091.6 crore.
In a notable development for its research pipeline, Zydus obtained FDA approval to conduct Phase II(b) clinical trials of Usnoflast for Amyotrophic Lateral Sclerosis (ALS), a condition that has also been granted Orphan Drug Designation by the regulator.
The news was published on February 5, 2025.
